These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 27613526

  • 1. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R, Varella-Garcia M, Li M, Ludkovski O, Danesh A, Ng C, Pham NA, Pugh T, Shepherd FA, Tsao MS.
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W, Zhang J, Guo L, Chuai S, Shan L, Ying J.
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
    Ilie MI, Bence C, Hofman V, Long-Mira E, Butori C, Bouhlel L, Lalvée S, Mouroux J, Poudenx M, Otto J, Marquette CH, Hofman P.
    Ann Oncol; 2015 Jan; 26(1):238-244. PubMed ID: 25344360
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ, Kim HR, Shim HS.
    J Transl Med; 2016 Oct 19; 14(1):296. PubMed ID: 27756333
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD, Zhang B, Gu Q, Lira M, Xu Q, Sun H, Qian M, Sheng W, Ozeck M, Wang Z, Zhang C, Chen X, Chen KX, Li J, Chen SH, Christensen J, Mao M, Chan CC.
    J Thorac Oncol; 2014 Mar 19; 9(3):285-94. PubMed ID: 24496003
    [Abstract] [Full Text] [Related]

  • 12. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 19; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 13. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
    Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ.
    Clin Chem; 2016 Jan 19; 62(1):252-61. PubMed ID: 26585927
    [Abstract] [Full Text] [Related]

  • 14. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].
    Wang Z, Wu X, Shi Y, Han X, Cheng G, Li L, Mu X, Zhang Y, Cui D, Zhang L, Fan Z, Zhu G, Ma L, Yang L, Di J, Liu D.
    Zhonghua Zhong Liu Za Zhi; 2015 Oct 19; 37(10):742-8. PubMed ID: 26813592
    [Abstract] [Full Text] [Related]

  • 15. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
    Wang Y, Zhang J, Gao G, Li X, Zhao C, He Y, Su C, Zhang S, Chen X, Zhang J, Li W, Li B, Zhao J, Hou L, Wu C, Ren S, Zhou C, Zhang J.
    J Thorac Oncol; 2015 Nov 19; 10(11):1546-52. PubMed ID: 26352533
    [Abstract] [Full Text] [Related]

  • 16. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Mengoli MC, Barbieri F, Bertolini F, Tiseo M, Rossi G.
    Lung Cancer; 2016 Mar 19; 93():55-8. PubMed ID: 26898615
    [Abstract] [Full Text] [Related]

  • 17. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP, Pathi N, Viswanath S, Rathore A, Pathak A, Sud R.
    Indian J Cancer; 2017 Mar 19; 54(1):203-208. PubMed ID: 29199691
    [Abstract] [Full Text] [Related]

  • 18. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.
    Oncologist; 2016 Jun 19; 21(6):762-70. PubMed ID: 27245569
    [Abstract] [Full Text] [Related]

  • 19. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
    Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR.
    J Thorac Oncol; 2014 Mar 19; 9(3):e21-3. PubMed ID: 24518095
    [No Abstract] [Full Text] [Related]

  • 20. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
    Demidova I, Barinov A, Savelov N, Gagarin I, Grinevitch V, Stroiakovaski D, Popov M, Laktionov K, Gutorov S, Smolin A, Olshanskaya Y, Obukhova T.
    Arch Pathol Lab Med; 2014 Jun 19; 138(6):794-802. PubMed ID: 24878018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.